AZN:LSEAstraZeneca PLC Analysis

AstraZeneca is trading in a bullish trend with price comfortably above its 20‑day and 50‑day moving averages, and volume remains stable, supporting the price move. The RSI sits just below the 50 mark, suggesting neutral momentum, while the MACD shows a bearish crossover, hinting at short‑term downside pressure. The stock benefits from a low beta, indicating limited sensitivity to broader market swings, yet 30‑day volatility is elevated at roughly 27%, reflecting sector‑specific swings. Current price sits near the identified resistance around £157 and well above the support level near £137, with an upside potential of about 13% relative to the DCF fair‑value estimate. Fundamentals are solid: revenue grew 4% YoY, gross margins exceed 80%, and operating margins are above 20%, while free cash flow remains robust, underpinning a sustainable dividend yield of 1.6% with a payout ratio under 50%. Recent material news highlights an 8% revenue jump in 2025, strategic collaborations with CSPC Pharmaceuticals and Tempus, and a successful $2 bn bond issuance, all of which reinforce the medium‑term growth narrative.
Valuation remains mixed: the DCF fair value suggests the stock is priced above intrinsic levels, yet analyst consensus targets around £163‑£168 imply further upside. The combination of a strong pipeline, dividend stability, and modest upside makes the stock a compelling hold for investors seeking a blend of growth and income in a low‑beta, globally diversified healthcare play.